[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial

Advancing cancer therapies. At the speed of light

Advancing cancer therapies. At the speed of light.

Hemerion® develops a unique and disruptive technology to treat glioblastoma.
A breakthrough therapy for glioblastoma patients

A breakthrough therapy for glioblastoma patients

Promising early clinical results

Promising early clinical results

A disruptive technology to tackle brain cancer and glioblastoma


Medical treatments trends innovation map Startus Insights

Hemerion One of 20 Emerging Healthtechs of 2023 for its Combination Therapy in the Treatment of Glioblastoma

September 22, 2023

Hemerion's technology is cited as an example of a major trend in healthcare innovation in StartUs Insights' 2023 report. Since 2014, StartUs Insights has analyzed the evolution of nearly 4… ...

Read more

Heliance devices shipped to Pittsburgh for the next Hemerion clinical trial

Glioblastoma clinical trial in Pittsburgh: Heliance® devices shipped to the USA

September 13, 2023

Hemerion's teams have taken the first step towards setting up a new clinical trial in the USA, with the shipment of a complete batch of Heliance® devices and its drug… ...

Read more

Hemerion addresses upfront management of newly diagnosed glioblastoma, during surgery, before any adjuvant treatment

Hemerion announces FDA clearance of IND application for its treatment of glioblastoma

July 5, 2023

Hemerion has received clearance from the US Food and Drug Administration (FDA) for the investigational new drug application (IND) for its Pentalafen® / Heliance® drug-device combination product for the treatment… ...

Read more

mail icon

Stay tuned to our clinical advances

Subscribe to our newsletter

They talk about us